Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 6, Issue 2 (2017)

Changes in systemic inflammation markers and severity of symptoms in chronic obstructive pulmonary disease patients receiving adequate basic therapy

Author(s):
Pertseva TO and Mihailichenko DS
Abstract:
Many studies show that systemic inflammation marker levels should be taken into account as a key factor causing extrapulmonary complications and progression of the disease. However, assessment of systemic inflammation severity is not always used in routine medical practice to determine the severity of COPD.
Aim: Determine the severity of systemic inflammation by measuring serum SAA and CRP levels during the stable phase of the disease in COPD patients who received different treatments.
Materials and Methods: We have examined 37 COPD patients. Patients examination included general clinical methods, questionnaires for detecting of severity of symptoms, detecting severity of systemic inflammation by measuring serum SAA and CRP levels. Patients were divided into two subgroups depending on the treatment which they received. Patients of both subgroups were screened twice – at baseline (visit 1) and three months after assignment of adequate standard therapy (visit 2).
Results: If treated inadequately, COPD patients in the stable phase, regardless of severity of their condition, suffer from more intense symptoms, have more relapses over the previous year, and their systemic inflammation levels are higher than in patients who receive long-term therapy adequate to their COPD. Proper three-month COPD treatment helps improve the symptoms to the levels found in patients who receive longer adequate therapy. As soon as three months after initiation, correctly assigned COPD treatment helps reduce systemic inflammation significantly by CRP levels and slightly by SAA levels.
Pages: 93-96  |  859 Views  17 Downloads
How to cite this article:
Pertseva TO, Mihailichenko DS. Changes in systemic inflammation markers and severity of symptoms in chronic obstructive pulmonary disease patients receiving adequate basic therapy. Pharma Innovation 2017;6(2):93-96.
The Pharma Innovation Journal